A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.

Int J Chron Obstruct Pulmon Dis · 2021 · PMC8075181 · PMID 33911859

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Compared to the placebo arm, ensifentrine generally provided numerically greater improvements at Week 4 in the E-RSTM: COPD total score and TDI score, but did not reach statistical significance ( Table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.